China Securities (601066) Report Interpretation

Overview

UBS reviews China Securities’ interim results, highlighting investment income and brokerage as the main drivers of strong Q2 earnings. The firm retains its Rmb20.30 price target and Sell rating under its P/B-ROE valuation approach.

Core views

China Securities reported H1 2026 revenue of Rmb16.2bn and recurring NPAT of Rmb7.8bn, up 51% and 74% year on year. Recurring profit was at the midpoint of the company’s preliminary Rmb7.3bn–Rmb8.2bn range. UBS estimates implied Q2 recurring NPAT of Rmb4.1bn, up 57% year on year and 14% quarter on quarter, although below UBS’s sector-average estimate of 76% year-on-year growth. Recurring ROE improved by 3.4 percentage points year on year to 8.4% in H1, while adjusted leverage rose by 0.6x to about 4.7x at end-June. The interim dividend was Rmb0.29 per share, implying an approximately 32% payout ratio, unchanged from H1 2025. Investment income was the principal earnings contributor. Net investment income rose 74% year on year in H1, implying Q2 income of Rmb4.6bn, up 71% year on year and 32% quarter on quarter. UBS links this to a sharp improvement in Q2 market conditions: the STAR 50, ChiNext and CSI 300 rose 76%, 36% and 12%, respectively, compared with -2%, 2% and 1% in Q2 2025 and -7%, -1% and -4% in Q1 2026. The report also identifies the company’s co-investment and proprietary exposure to technology-industry leaders including CXMT and YMTC as a potential earnings tailwind. Brokerage net revenue increased 51% year on year in H1, implying Q2 growth of 66% year on year and 12% quarter on quarter. This lagged the 1.3x year-on-year and 7.3% quarter-on-quarter increase in A-share equity-linked average daily turnover, which UBS says suggests year-on-year fee pressure remained. Financial-product distribution revenue rose 56% year on year and 16% half on half, supported by stronger retail risk appetite as sentiment improved; the CSI 300 gained 7.6% in H1 2026, versus 0% in H1 2025 and 18% in H2 2025. Other businesses were mixed. Investment-banking net revenue fell 1% year on year in H1, implying Q2 declines of 34% year on year and 18% quarter on quarter. China Securities’ A-share IPO market share fell about 39 percentage points year on year and 7 percentage points quarter on quarter to roughly 1%, despite industry A-share IPO fundraising reaching Rmb45bn, up 1.1x year on year and 73% quarter on quarter. In Hong Kong, its IPO market share was 5.5%, down 4.3 percentage points year on year but up 3.8 percentage points quarter on quarter as market-wide issuance exceeded HK$100bn. UBS nevertheless notes a healthy pipeline of 35 A-share and 26 H-share mandates as of 18 August. Asset-management net revenue rose 16% year on year in H1; self-branded AUM increased 29% year on year at end-June, ahead of roughly 17% growth for industry broker AUM. Net interest income grew 71% year on year in H1 but implied Q2 declines of 78% year on year and 88% quarter on quarter. Overseas revenue rose 24% year on year and 11% half on half, but its group-revenue share fell to 5.4% from about 6.6% in H1 2025 and 6.2% in H2 2025. UBS maintains its Rmb20.30 price target and Sell rating, using P/B-ROE methodology. At the 18 August 2026 price of Rmb25.43, the report shows forecast price appreciation of -20.2%, forecast dividend yield of 1.9%, and forecast stock return of -18.3%, versus a 6.8% market-return assumption, producing forecast excess return of -25.0%. UBS forecasts 2026 EPS of Rmb1.57, ROE of 9.8% and P/BV of 1.5x; its EPS estimate is above consensus of Rmb1.46.

Analysis framework

UBS starts with reported H1 results and derives implied Q2 profit and business-line performance. It compares these trends with market indices, A-share turnover, industry fundraising and peer AUM growth, then assesses the contribution and volatility of each operating segment. The valuation conclusion applies a price-to-book framework linked to expected ROE and compares the resulting 12-month return with UBS’s market-return assumption.

Methodology notes

• Valuation methodsPB valuation

  P/B-ROE methodology

  UBS values the company using price-to-book relative to expected return on equity, linking the target price to the profitability that the firm expects the brokerage to earn on its book value.

• Corporate Fundamentals and FinanceROIC–WACC spread

  Return-on-equity analysis

  The report tracks recurring ROE and forecast ROE as key indicators of profitability, including a 3.4 percentage-point year-on-year improvement to 8.4% in H1 2026.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China Securities (601066.SH)

  The covered company benefited from stronger investment income and brokerage activity in Q2, but UBS retains a Sell rating based on its P/B-ROE valuation.

  Strengths

  Investment income growth, brokerage and product-distribution growth, 29% growth in self-branded AUM, and a healthy IPO mandate pipeline.

  Weaknesses

  Investment-banking revenue decline, a roughly 1% A-share IPO market share in Q2, persistent brokerage fee pressure, and sharply lower implied Q2 net interest income.

  Comparison

  Implied Q2 recurring NPAT growth of 57% year on year was below UBS’s sector-average estimate of 76%; self-branded AUM growth of 29% exceeded roughly 17% industry broker AUM growth.

  Risks

  A prolonged A-share downturn, slower development of innovative businesses and intensified brokerage competition could pressure earnings and valuation multiples.

Key data

• H1 2026 revenueRmb16.2bnUp 51% year on year.
• H1 2026 recurring NPATRmb7.8bnUp 74% year on year; within the Rmb7.3bn–Rmb8.2bn preliminary range.
• Implied Q2 recurring NPATRmb4.1bnUp 57% year on year and 14% quarter on quarter.
• H1 recurring ROE8.4%Up 3.4 percentage points year on year.
• Q2 implied investment incomeRmb4.6bnUp 71% year on year and 32% quarter on quarter.
• 2026E EPSRmb1.57UBS estimate versus consensus of Rmb1.46.
• Forecast stock return-18.3%Comprises -20.2% forecast price appreciation and 1.9% dividend yield.

Impact & implications

UBS considers the earnings recovery to be driven chiefly by improved market conditions and investment and brokerage activity. However, fee pressure, weak investment-banking execution and volatility in net interest income remain material offsets, while the valuation framework supports a Sell conclusion at the stated price.

Risks

• Stronger-than-expected A-share market activity and improving investor sentiment could create upside risk.
• Faster-than-expected regulatory rollouts, particularly in investment banking and derivatives, could support the stock.
• Stronger business execution could lead to earnings outperformance relative to UBS expectations.
• A prolonged A-share downturn could weaken broker earnings and cause multiple de-rating.
• Slower development of innovative business segments could weigh on performance.
• More intense brokerage competition could prolong commission-rate compression over the medium to long term.